Long-term treatment with proton pump inhibitor is associated with undesired weight gain

被引:23
作者
Yoshikawa, Ichiro [1 ]
Nagato, Makiko [1 ]
Yamasaki, Masahiro [1 ]
Kume, Keiichiro [1 ]
Otsuki, Makoto [1 ]
机构
[1] Univ Occupat & Environm Hlth, Dept Internal Med 3, Sch Med, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
关键词
Gastroesophageal reflux disease; Proton pump inhibitor; Body weight; GASTROESOPHAGEAL-REFLUX DISEASE; RISK-FACTORS; BODY-MASS; SYMPTOMS; OMEPRAZOLE; OBESITY; PREVALENCE; PATIENT;
D O I
10.3748/wjg.15.4794
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
AIM: To examine the effects of long-term proton pump inhibitor (PPI) therapy on body weight (BW) and body mass index (BMI) in patients with gastroesophageal reflux disease (GERD). METHODS: The subjects were 52 patients with GERD and 58 sex- and age-matched healthy controls. GERD patients were treated with PPI for a mean of 2.2 years (range, 0.8-5.7 years), and also advised on lifestyle modifications (e.g. selective diet, weight management). BW, BMI and other parameters were measured at baseline and end of study, RESULTS: Twenty-four GERD patients were treated daily with 10 mg omeprazole, 12 with 20 mg omeprazole, 8 with 10 mg rabeprazole, 5 with 15 mg lansoprazole, and 3 patients with 30 mg lansoprazole. At baseline, there were no differences in BW and BMI between reflux patients and controls. Patients with GERD showed increases in BW (baseline: 56.4 +/- 10.4 kg, end: 58.6 +/- 10.8 kg, mean +/- SD, P < 0.0001) and BMI (baseline. 23.1 +/- 3.1 kg/m(2), end: 24.0 +/- 3.1 kg/m(2), P < 0.001), but no such changes were noted in the control group. Mean BW increased by 3.5 kg (6.2% of baseline) in 37 (71%) reflux patients but decreased in only 6 (12%) patients during treatment. CONCLUSION: Long-term PPI treatment was associated with BW gain in patients with GERD. Reflux patients receiving PPI should be encouraged to manage BW through lifestyle modifications. (C) 2009 The WJG Press and Baishideng. All rights reserved.
引用
收藏
页码:4794 / 4798
页数:5
相关论文
共 26 条
[1]
Dual effects of rabeprazole on solid-phase gastric emptying assessed by the 13C-octanoate breath test [J].
Anjiki, H ;
Sanaka, M ;
Kuyama, Y .
DIGESTION, 2005, 72 (2-3) :189-194
[2]
[Anonymous], 2000, Arch Intern Med, V160, P898
[3]
Omeprazole causes delay in gastric emptying of digestible meals [J].
Benini, L ;
Castellani, G ;
Bardelli, E ;
Sembenini, C ;
Brentegani, MT ;
Caliari, S ;
Vantini, I .
DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (03) :469-474
[4]
Blair DI, 1997, J FAM PRACTICE, V44, P266
[5]
Updated guidelines for the diagnosis and treatment of Gastroesophageal reflux disease [J].
DeVault, KR ;
Castell, DO .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (01) :190-200
[6]
Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population [J].
Diaz-Rubio, M ;
Moreno-Elola-Olaso, C ;
Rey, E ;
Locke, GR ;
Rodriguez-Artalejo, F .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (01) :95-105
[7]
Obesity is an independent risk factor for GERD symptoms and erosive esophagitis [J].
El-Serag, HB ;
Graham, DY ;
Satia, JA ;
Rabeneck, L .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (06) :1243-1250
[8]
Fraser-Moodie CA, 1999, SCAND J GASTROENTERO, V34, P337, DOI 10.1080/003655299750026326
[9]
Gut flora in health and disease [J].
Guarner, F ;
Malagelada, JR .
LANCET, 2003, 361 (9356) :512-519
[10]
Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications [J].
Hampel, H ;
Abraham, NS ;
El-Serag, HB .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (03) :199-211